Document Detail

Controversies about the treatment of myasthenia gravis.
MedLine Citation:
PMID:  7400825     Owner:  NLM     Status:  MEDLINE    
Clinicians treating patients with myasthenia gravis must choose cholinergic drugs, corticosteroids, immunosuppressive drugs, thymectomy, or plasmapheresis. Clinicians must decide the sequence or combination of these therapies and when to deem lack of improvement a sign for a different therapeutic approach. Because controlled trials have not been done to evaluate therapies that may require months or years before benefit is evident, controversy abounds.
L P Rowland
Related Documents :
782235 - Drug therapy in colonial and revolutionary america.
2178755 - New antiemetic drugs.
12197605 - Interstitial pneumonia induced by ticlopidine.
23618965 - Functional alginate nanoparticles for efficient intracellular release of doxorubicin an...
11154085 - Methylene blue mediated photodynamic therapy in experimental colorectal tumors in mice.
7192495 - Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled c...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of neurology, neurosurgery, and psychiatry     Volume:  43     ISSN:  0022-3050     ISO Abbreviation:  J. Neurol. Neurosurg. Psychiatr.     Publication Date:  1980 Jul 
Date Detail:
Created Date:  1980-10-24     Completed Date:  1980-10-24     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  2985191R     Medline TA:  J Neurol Neurosurg Psychiatry     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  644-59     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholinesterase Inhibitors / therapeutic use
Dose-Response Relationship, Drug
Immunosuppressive Agents / therapeutic use
Myasthenia Gravis / therapy*
Parasympathomimetics / therapeutic use
Steroids / therapeutic use
Reg. No./Substance:
0/Cholinesterase Inhibitors; 0/Immunosuppressive Agents; 0/Parasympathomimetics; 0/Steroids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immune regulation of experimental myasthenia.
Next Document:  Exercise thallium imaging: location of perfusion abnormalities in single-vessel coronary disease.